Brian Adams Biography and Net Worth

Chief Legal Officer and Corporate Secretary of Kymera Therapeutics

As Chief Legal Officer, Brian leads Kymera’s legal, governance, and intellectual property functions. Brian has over two decades of leadership in the life sciences, spanning legal affairs, IP, corporate development, strategic planning, and governance. Before joining Kymera, he was Chief Legal Officer of Relay Therapeutics, where he built and led Relay’s legal and compliance operations as well as many of its operational functions. Prior to Relay, he served as Senior Vice President, General Counsel at Keryx Biopharmaceuticals and held senior roles at Algeta ASA, AVEO Oncology, and Genzyme Corporation. Brian began his legal career in private practice at Bingham McCutchen LLP. He holds a B.A. from Harvard University and a J.D. from the Catholic University of America’s Columbus School of Law.

What is Brian Adams' net worth?: The estimated net worth of Brian Adams is at least $5.99 million as of September 4th, 2026. Mr. Adams owns 50,254 shares of Kymera Therapeutics stock worth more than $5,990,779 as of September 8th. This net worth estimate does not reflect any other investments that Mr. Adams may own. Learn More about Brian Adams' net worth.
How do I contact Brian Adams?: The corporate mailing address for Mr. Adams and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Brian Adams' contact information.
Has Brian Adams been buying or selling shares of Kymera Therapeutics?: During the past quarter, Brian Adams has sold $744,323.93 in shares of Kymera Therapeutics stock. Most recently, Brian Adams sold 6,371 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a transaction totalling $744,323.93. Following the completion of the sale, the insider now directly owns 50,254 shares of the company's stock, valued at $5,871,174.82. Learn More on Brian Adams' trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Brian Adams (Chief Legal Officer and Corporate Secretary), Jeffrey Albers (Director), Bruce Booth (Director), Jeremy Chadwick (COO), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Noah Goodman (Chief Business Officer), Bruce Jacobs (CFO), Nello Mainolfi (CEO), and Elena Ridloff (Director). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, Kymera Therapeutics insiders bought shares 1 times. They purchased a total of 2,005,813 shares worth more than $172,499,918.00. In the last twelve months, insiders at the sold shares 64 times. They sold a total of 4,622,723 shares worth more than $469,937,228.91. The most recent insider tranaction occured on September, 4th when insider Brian Adams sold 6,371 shares worth more than $744,323.93. Insiders at Kymera Therapeutics own 16.0% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 9/4/2026.

Brian Adams Insider Trading History at Kymera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/4/2026	Sell	6,371	$116.83	$744,323.93	50,254

Brian Adams Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $117.56

$113.97

$120.22

50 Day Range

MA: $114.32

$100.31

$127.31

2 Week Range

Now: $117.56

$42.71

$130.05

Volume

327,453 shs

Average Volume

731,319 shs

Market Capitalization

$9.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96